Stem Cell Therapy for ALS

Amyotrophic lateral sclerosis (ALS), the progressive motor neuron disease also known as Lou Gehrig's disease, has no cure, and current drugs offer only modest slowing of decline. That gap has made stem cell therapy one of the most closely watched areas of ALS research for two decades. This article explains how these therapies are thought to work, what the strongest clinical trials have actually shown, where a version is approved (South Korea, not the US), and what realistic candidacy looks like today.

How It's Thought to Work

Most ALS stem cell approaches use mesenchymal stem cells (MSCs), often engineered or cultured to secrete extra neurotrophic factors (MSC-NTF cells). The idea isn't to replace dying motor neurons directly. Instead, the cells are meant to act like a local pharmacy: delivered into the spinal fluid, they release growth factors and anti-inflammatory signals intended to protect surviving motor neurons, calm the immune and glial activity that drives ALS progression, and potentially slow — not reverse — functional decline. This is fundamentally a neuroprotective strategy, not a regenerative or curative one.

What the Evidence Shows

The most rigorously tested MSC-NTF therapy is NurOwn (debamestrocel), developed by BrainStorm Cell Therapeutics. Its Phase 3 trial, published in Muscle & Nerve (Cudkowicz et al., 2022), missed its primary endpoint: 34.7% of NurOwn-treated patients were "responders" versus 27.7% on placebo, a difference that did not reach statistical significance. That's an honest result, and it matters. But a corrected post-hoc analysis found something genuinely encouraging: among participants with less advanced disease at baseline (ALSFRS-R score ≥35), NurOwn produced a statistically significant treatment benefit of more than two points on the functional rating scale compared to placebo — a signal strong enough that BrainStorm pursued FDA approval on its strength. That pursuit, however, ran into a hard wall: the FDA issued a refusal-to-file letter in late 2022, an advisory committee voted 17–1 against approval in September 2023 citing insufficient evidence of effectiveness and manufacturing concerns, and BrainStorm withdrew its application shortly after. The FDA has since cleared a new Phase 3b trial (2025) to try to confirm the earlier subgroup finding.

In South Korea, Corestem's lenzumestrocel (Neuronata-R) has held conditional orphan-drug approval from the Ministry of Food and Drug Safety since the early 2010s — the first licensed stem cell therapy for ALS anywhere. Its completed Phase 3 (ALSUMMIT) trial did not reach significance across the full study population, but in a "slow progressor" subgroup it met its primary combined function-and-survival endpoint, along with secondary improvements in functional scores, breathing capacity, and a biomarker of nerve damage (neurofilament light chain) — encouraging enough that Korean regulators renewed the license in 2026 based on that data, and the company is now pursuing a US regulatory pathway.

Beyond these two programs, numerous Phase 1/2 trials (academic and industry-sponsored, in the US, Europe, and Asia) using bone marrow-derived, umbilical cord-derived, or neural progenitor stem cells have consistently shown these interventions are generally safe and tolerable, with occasional signals of slowed decline — but none have produced the large, unambiguous efficacy data regulators require (ClinicalTrials.gov; ALS Association research updates).

Who Might Be a Candidate

• No stem cell therapy is FDA-approved for ALS in the United States; the FDA has explicitly stated regenerative products have not been approved to treat ALS or any other neurological disease.
• Outside the US, Neuronata-R is approved only in South Korea, under a narrow, conditional label — it is not a treatment routinely accessible to international patients, and eligibility, dosing protocol, and monitoring are set by Korean regulators and the treating center.
• In the US and most of the world, access to any ALS stem cell therapy realistically means enrolling in a registered clinical trial (searchable at ClinicalTrials.gov), typically with criteria around diagnosis certainty, disease duration, and baseline functional status — earlier-stage, more slowly progressing patients have shown the clearest signals in trial subgroup data so far.
• Patients considering trial enrollment should discuss options with an ALS specialist or a multidisciplinary ALS clinic, and should be wary of clinics marketing "stem cell treatments" for ALS outside of a registered trial — these fall under the FDA's unapproved-product warnings and carry real safety risk with no proven benefit.
• Anyone pursuing a trial should ask specifically about the cell type used, delivery route (often intrathecal injection), and whether the study is a registered, blinded, placebo-controlled design — this is where credible evidence comes from.

Bottom Line

ALS stem cell therapy is not a proven cure, and no version of it carries FDA approval in the United States today. That said, the field has moved past pure speculation: NurOwn's Phase 3 program, despite missing its overall primary endpoint, produced a real and statistically significant benefit in a meaningful subgroup of patients, and Neuronata-R's subgroup data was strong enough to earn — and keep — a national regulatory approval in South Korea. Both programs are now pushing for larger, more targeted confirmatory trials rather than folding, which is a genuinely hopeful sign for a disease with so few therapeutic options. For now, though, the honest picture is one of promising but unconfirmed evidence: safety is generally well established, efficacy is not yet proven at the population level, and clinical trial enrollment — not commercial treatment — is the responsible path forward for most patients.